Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder.
EPA
alcohol-associated liver disease
random forest
sphingomyelin
steatosis
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
11 May 2022
11 May 2022
Historique:
received:
20
04
2022
revised:
04
05
2022
accepted:
04
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Alcohol-related liver disease is a public health care burden globally. Only 10-20% of patients with alcohol use disorder have progressive liver disease. This study aimed to identify lipid biomarkers for the early identification of progressive alcohol-related liver disease, which is a key step for early intervention. We performed untargeted lipidomics analysis in serum and fecal samples for a cohort of 49 subjects, including 17 non-alcoholic controls, 16 patients with non-progressive alcohol-related liver disease, and 16 patients with progressive alcohol-related liver disease. The serum and fecal lipidome profiles in the two patient groups were different from that in the controls. Nine lipid biomarkers were identified that were significantly different between patients with progressive liver disease and patients with non-progressive liver disease in both serum and fecal samples. We further built a random forest model to predict progressive alcohol-related liver disease using nine lipid biomarkers. Fecal lipids performed better (Area Under the Curve, AUC = 0.90) than serum lipids (AUC = 0.79). The lipid biomarkers identified are promising candidates for the early identification of progressive alcohol-related liver disease.
Identifiants
pubmed: 35629937
pii: metabo12050433
doi: 10.3390/metabo12050433
pmc: PMC9146183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK120515
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA011999
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA024726
Pays : United States
Organisme : NIAAA NIH HHS
ID : R37 AA020703
Pays : United States
Références
PLoS One. 2009;4(5):e5601
pubmed: 19440307
Nat Methods. 2015 Jun;12(6):523-6
pubmed: 25938372
Nat Commun. 2020 May 18;11(1):2471
pubmed: 32424203
Alcohol Res. 2017;38(2):147-161
pubmed: 28988570
Gastroenterology. 2015 Jan;148(1):203-214.e16
pubmed: 25239591
Am J Clin Nutr. 1999 Nov;70(5):928-36
pubmed: 10539756
J Lipid Res. 2011 Nov;52(11):2021-31
pubmed: 21856784
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:38-42
pubmed: 23855294
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Anal Chem. 2017 Mar 21;89(6):3250-3255
pubmed: 28225594
Front Nutr. 2019 Apr 10;6:36
pubmed: 31024921
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17808-13
pubmed: 24127592
Mol Nutr Food Res. 2015 Aug;59(8):1603-13
pubmed: 25820326
J Lipid Res. 1973 Jan;14(1):78-86
pubmed: 4349663
Nucleic Acids Res. 2020 Jan 8;48(D1):D445-D453
pubmed: 31586394
Metabolites. 2019 Apr 26;9(5):
pubmed: 31035489
Bull Exp Biol Med. 2008 Dec;146(6):753-5
pubmed: 19513375
J Cardiovasc Pharmacol. 2009 Mar;53(3):198-208
pubmed: 19247196
Cell Host Microbe. 2020 Aug 12;28(2):233-244
pubmed: 32791115
Alcohol Alcohol. 2016 May;51(3):251-7
pubmed: 26511776
Alcohol Clin Exp Res. 2011 Feb;35(2):229-34
pubmed: 21058963
Pancreas. 2009 Mar;38(2):e47-52
pubmed: 19248221
Nature. 2019 Nov;575(7783):505-511
pubmed: 31723265
J Hepatol. 2019 Feb;70(2):237-248
pubmed: 30658725
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
PLoS One. 2015 Jun 24;10(6):e0130346
pubmed: 26107182
Nat Methods. 2018 Nov;15(11):962-968
pubmed: 30377376
Gastroenterology. 2014 Aug;147(2):377-84.e1
pubmed: 24818764
Gut Microbes. 2020 Nov 9;12(1):1782157
pubmed: 32588725